539 related articles for article (PubMed ID: 27873264)
21. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
23. EBV-Encoded Latent Genes.
Kanda T
Adv Exp Med Biol; 2018; 1045():377-394. PubMed ID: 29896676
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Martin KA; Lupey LN; Tempera I
J Virol; 2016 Oct; 90(19):8520-30. PubMed ID: 27440880
[TBL] [Abstract][Full Text] [Related]
25. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
26. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
27. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.
Kelly GL; Long HM; Stylianou J; Thomas WA; Leese A; Bell AI; Bornkamm GW; Mautner J; Rickinson AB; Rowe M
PLoS Pathog; 2009 Mar; 5(3):e1000341. PubMed ID: 19283066
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1.
Watanabe A; Maruo S; Ito T; Ito M; Katsumura KR; Takada K
J Virol; 2010 Mar; 84(6):2893-901. PubMed ID: 20042495
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
31. Exosomes released in vitro from Epstein-Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs.
Canitano A; Venturi G; Borghi M; Ammendolia MG; Fais S
Cancer Lett; 2013 Sep; 337(2):193-9. PubMed ID: 23684926
[TBL] [Abstract][Full Text] [Related]
32. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia.
Niller HH; Wolf H; Minarovits J
Semin Cancer Biol; 2009 Jun; 19(3):158-64. PubMed ID: 19429479
[TBL] [Abstract][Full Text] [Related]
34. Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors.
Chen X; Kamranvar SA; Masucci MG
Oncogene; 2016 Jul; 35(29):3807-16. PubMed ID: 26592445
[TBL] [Abstract][Full Text] [Related]
35. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.
Vrzalikova K; Vockerodt M; Leonard S; Bell A; Wei W; Schrader A; Wright KL; Kube D; Rowe M; Woodman CB; Murray PG
Blood; 2011 Jun; 117(22):5907-17. PubMed ID: 21411757
[TBL] [Abstract][Full Text] [Related]
37. Proteomic profiling of EBNA1-host protein interactions in latent and lytic Epstein-Barr virus infections.
Malik-Soni N; Frappier L
J Virol; 2012 Jun; 86(12):6999-7002. PubMed ID: 22496234
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic Alterations in Epstein-Barr Virus-Associated Diseases.
Niller HH; Banati F; Salamon D; Minarovits J
Adv Exp Med Biol; 2016; 879():39-69. PubMed ID: 26659263
[TBL] [Abstract][Full Text] [Related]
39. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
40. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
